News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TARIS Biomedical Initiates Clinical Study in Interstitial Cystitis Patients



3/9/2011 10:33:00 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS’ innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC. LiRIS® is designed to continuously deliver lidocaine over an extended period directly to the bladder to decrease symptoms associated with IC, such as bladder pain and voiding dysfunction.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES